EGFR and non-small cell lung carcinoma: Two phase I/II trials tested the efficacy of Buparlisib in combination with either thoracic radiotherapy or with Erlotinib, an EGFR inhibitor in non-small-cell lung cancer (NSCLC) patients [142,143].